Global Coalition for Adaptive Research
  • Leadership
  • GBM AGILE
    • About GBM AGILE
    • GBM AGILE Trial Sites
    • FAQs
    • Strategic Partners
  • News
  • Join Us
  • Contact
  • DONATE
Global Coalition for Adaptive Research

Home of the GBM AGILE trial,
our mission is to speed the
discovery and development of
cures for patients with rare
and deadly diseases.

GBM AGILE: Now Enrolling

Info     Press release

INITIAL GOALS

Operationalize GBM AGILE into a self-sustaining
engine of therapeutic and biomarker development
for patients with GBM.
Finance the launch and ongoing activity of new
GBM-focused therapies developed through
GBM AGILE.
Use GBM AGILE as a model for developing an efficient
framework for the discovery and development of
therapies and biomarkers for other rare and deadly diseases.
Randall Garnick Photography, National Brain Tumor Society

LEADERSHIP

The Global Coalition for Adaptive Research (GCAR) is an international partnership


The Global Coalition for Adaptive Research (GCAR) is an international partnership comprised of some of the world’s foremost clinical, translational, and basic science investigators. Through this collaboration and open exchange of ideas, the ultimate beneficiary—the patient—is supported in the fight against rare and deadly diseases.

READ MORE

GBM AGILE is a seamless Phase II (Efficacy and Safety) / Phase III (Confirmatory) trial to identify effective therapies and the most promising biomarker-defined populations for those therapies in patients with glioblastoma.

GBM AGILE is changing the IDEA of clinical trials

Innovative – Next-generation trial that will lower cost of development and speed progress.

Dynamic – Perpetual learning system to quickly add potentially promising new drugs and drop those that appear to be ineffective.

Efficient – Design and trial structure that will require fewer patients and a shorter time frame to get important answers about a drug's effectiveness.

Accessible – Global effort open to a broad patient population of newly diagnosed and recurrent GBM patients.
LEARN MORE

NEWS


Global Coalition for Adaptive Research’s Innovative Clinical Trial Platform Opens to Evaluate New Therapies for Brain Cancer
JUNE 19, 2019  |  BUSINESS WIRE
Global Coalition for Adaptive Research (GCAR) Appoints Jeffrey Tarrant to Board of Directors
JUNE 13, 2019  |  BUSINESS WIRE
FDA’s Woodcock Defends Accelerated Approvals and Talks of Culture Shift in Clinical Trials
JUNE 5, 2019  |  BIOPHARMA DIVE
New Funding & Partnership Bolsters Support for First Global Adaptive Clinical Trial Platform for Brain Cancer Patients
MAY 1, 2019  |  NATIONAL BRAIN TUMOR SOCIETY
Global Coalition for Adaptive Research (GCAR) Names Meredith Buxton Chief Operating Officer
JANUARY 31, 2019  |  GLOBAL COALITION FOR ADAPTIVE RESEARCH
National Brain Tumor Society Invests in GBM AGILE, the World’s First Global Adaptive Trial for Glioblastoma
JANUARY 16, 2019  |  NATIONAL BRAIN TUMOR SOCIETY
Bayer’s Regorafenib is the First Drug to Enter GBM AGILE
NOVEMBER 14, 2018  |  BUSINESSWIRE
Global Coalition for Adaptive Research (GCAR) Names Gary Gordon Interim Chief Executive Officer
NOVEMBER 8, 2018  |  PRWEB
4 Ways Cancer is Changing How We Test Medicines
OCTOBER 18, 2018  |  POLITICO
Dr. W.K. Alfred Yung Addresses Members of U.S. Congress at Glioblastoma Event Hosted by NBTS, Senator Lindsey Graham
May 16, 2018  |  National Brain Tumor Society
ALL NEWS

GET INVOLVED

MAKE A DONATION
STAY CONNECTED
SUBSCRIBE NOW!
×

Subscribe to our mailing list

* indicates required
I am a:

CONTACT US

For additional information about GCAR and to learn how you can collaborate with us, please contact:
GENERAL INQUIRIES
MEDIA INQUIRIES
Copyright © 2019  Global Coalition for Adaptive Research. All Rights Reserved. 617-299-6471
The Global Coalition for Adaptive Research is registered as a 501(c)(3) nonprofit organization. Contributions to the Global Coalition for Adaptive Research are tax-deductible to the extent permitted by law.
Privacy  •  Design by Mintwich Creative  •  Development by Example 7
  • Home
  • Leadership
  • GBM AGILE
    • About GBM AGILE
    • GBM AGILE Trial Sites
    • FAQs
    • Strategic Partners
  • News
  • Join Us
  • Contact
  • DONATE